inebilizumab
-
Open CD19-B Cell Depletion in PAIS-ME/CFS Patients (PIONEER_PAIS) [Berlin, Germany - Study of Inebilizumab]
Official title Prospective, Randomized, Double-blind, Placebo-controlled Phase 2b Trial Evaluating the Efficacy and Safety of the Anti-CD19 Monoclonal Antibody Inebilizumab Compared With Placebo in Patients With Post-acute Infection Syndromes Fulfilling ME/CFS Criteria (PIONEER) Brief summary...- forestglip
- Thread
- inebilizumab
- Replies: 16
- Forum: Recruitment into current ME/CFS research studies